Egfrviii
Mostrando 1-7 de 7 artigos, teses e dissertações.
-
1. Análise da expressão, amplificação e deleção de EGFR e sua co-expressão com IL13R2 em astrocitomas / Analysis of EGFR expression, amplification and deletion and its coexpression with IL13R 2 in astrocytomas
O Receptor do Fator de Crescimento Epidérmico (do inglês, EGFR) é uma proteína de membrana celular que consiste em um domínio extracelular para o acoplamento do ligante e em um domínio intracelular apresentando sítio catalítico de tirosinoquinase. Em ~40% dos GBMs primários é observada a amplificação de EGFR resultando na sua hiperexpressão, o q
Publicado em: 2009
-
2. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display
EGFRvIII is a mutant epidermal growth factor receptor found in glioblastoma, and in carcinoma of the breast, ovary, and lung. The mutant receptor has a deletion in its extracellular domain that results in the formation of a new, tumor-specific extracellular sequence. Mice were immunized with a synthetic peptide corresponding to this sequence and purifie
The National Academy of Sciences of the USA.
-
3. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors
The epidermal growth factor receptor (EGFR) is often amplified and rearranged structurally in tumors of the brain, breast, lung, and ovary. The most common mutation, EGFRvIII, is characterized by an in-frame deletion of 801 base pairs, resulting in the generation of a novel tumor-specific epitope at the fusion junction. A murine homologue of the human EGFRvI
The National Academy of Sciences.
-
4. A TVA–Single-Chain Antibody Fusion Protein Mediates Specific Targeting of a Subgroup A Avian Leukosis Virus Vector to Cells Expressing a Tumor-Specific Form of Epidermal Growth Factor Receptor
We have previously described an approach that employs retroviral receptor-ligand bridge proteins to target retroviral vectors to specific cell types. To determine whether targeted retroviral entry can also be achieved using a retroviral receptor–single-chain antibody bridge protein, the TVA-MR1 fusion protein was generated. TVA-MR1 is comprised of the extr
American Society for Microbiology.
-
5. Proteomic and immunologic analyses of brain tumor exosomes
Brain tumors are horrific diseases with almost universally fatal outcomes; new therapeutics are desperately needed and will come from improved understandings of glioma biology. Exosomes are endosomally derived 30–100 nm membranous vesicles released from many cell types into the extracellular milieu; surprisingly, exosomes are virtually unstudied in neuro-o
The Federation of American Societies for Experimental Biology.
-
6. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases
Alterations of the epidermal growth factor receptor (EGFR) gene occur frequently in human malignant gliomas. The most common of these is deletion of exons 2–7, resulting in truncation of the extracellular domain (ΔEGFR or EGFRvIII), which occurs in a large fraction of de novo malignant gliomas (but not in progressive tumors or those lacking p53 function)
The National Academy of Sciences.
-
7. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478
Blockade of epidermal growth factor receptor (EGFR) signaling with specific inhibitors of the EGFR tyrosine kinase retards cellular proliferation and arrests the growth of tumor xenografts. AG1478, an inhibitor of the EGFR tyrosine kinase, is used in laboratory studies; however, its therapeutic potential has not been elucidated. Therefore, we evaluated an aq
National Academy of Sciences.